Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

NCT02474706 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Lack of recruitment

Conditions

Urinary Tract Infections

Interventions

DRUG: Cefoxitin
DRUG: imipenem

Sponsor

Central Hospital, Nancy, France